BioCentury
ARTICLE | Clinical News

Sarasar lonafarnib: Phase II started

February 1, 2016 8:00 AM UTC

Eiger began the open-label, dose-escalation, German Phase II LOWR HDV-4 trial to evaluate 50-75 mg oral lonafarnib twice daily plus oral ritonavir twice daily for 6 months in 15 patients. In 2010, Eig...